| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
Tetrapeptide-30 targets tyrosinase, the key enzyme in melanin synthesis. By inhibiting tyrosinase, the compound reduces the production of melanin, which is responsible for skin pigmentation. It acts by reducing the amount of tyrosinase and inhibiting melanocyte activation. This mechanism makes it effective for lightening hyperpigmentation and evening skin tone.
|
|---|---|
| ln Vitro |
UVB-induced IL-6, TNF-α, and POMC (proopioid melanocorticoid) gene expression can all be successfully reduced by tetrapeptide-30 (0–10 μg/mL, 24 h), as well as IL-8 gene expression [1]. In microemulsion form, tetrapeptide-30 (PKEK) has good skin penetration and is very hydrophilic [2].
In vitro, Tetrapeptide-30 acts as a tyrosinase inhibitor. It reduces the amount of tyrosinase and inhibits melanocyte activation. These activities have been demonstrated in cell-based assays. Specific IC50 values for tyrosinase inhibition are not provided in the available sources. |
| ln Vivo |
In vivo, Tetrapeptide-30 is used in cosmetic products for its skin-brightening effects. It is suitable for all skin tones and has anti-aging effects. Specific in vivo efficacy data, such as clinical trial results, are not detailed in the available sources.
|
| Enzyme Assay |
A cell-free assay for Tetrapeptide-30 would involve measuring its inhibition of tyrosinase enzymatic activity. In this assay, the enzyme is incubated with a substrate (e.g., L-DOPA) in the presence of varying concentrations of the compound. The production of melanin or a colored product is measured, and the IC50 is calculated.
|
| Cell Assay |
Cellular assays for Tetrapeptide-30 typically involve assessing its effects on melanin production in melanocytes. Cells are treated with the compound, and melanin content is measured. The expression of tyrosinase and other melanogenesis-related genes can also be assessed.
|
| Animal Protocol |
In vivo animal experiments for Tetrapeptide-30 are not described in the available sources. As a cosmetic ingredient, its efficacy is typically evaluated in human clinical trials rather than animal models.
|
| ADME/Pharmacokinetics |
Tetrapeptide-30 has a molecular formula of C22H40N6O7 and a molecular weight of 500.59 g/mol. Its CAS number is 1036207-61-0. The compound is a solid. Specific pharmacokinetic properties are not applicable as it is a cosmetic ingredient rather than a therapeutic drug. For storage, it should be kept in a cool, dry place.
|
| Toxicity/Toxicokinetics |
Toxicity data for Tetrapeptide-30 are not provided in the available sources. As a cosmetic ingredient, it is generally considered safe for topical use. However, specific toxicological information is not available.
|
| References |
|
| Additional Infomation |
Tetrapeptide-30 (CAS: 1036207-61-0) is a skin-brightening peptide. Its synonyms include Skin-brightening peptide. The compound is a tyrosinase inhibitor used in cosmetic and dermatological applications. It is not a therapeutic drug and is strictly for cosmetic and research purposes.
|
| Molecular Formula |
C22H40N6O7
|
|---|---|
| Molecular Weight |
500.589005470276
|
| Exact Mass |
500.295
|
| CAS # |
1036207-61-0
|
| PubChem CID |
25001762
|
| Appearance |
White to off-white solid powder
|
| Density |
1.256±0.06 g/cm3(Predicted)
|
| Boiling Point |
931.5±65.0 °C(Predicted)
|
| LogP |
-8.3
|
| Hydrogen Bond Donor Count |
8
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
18
|
| Heavy Atom Count |
35
|
| Complexity |
720
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C1C[C@H](NC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O
|
| InChi Key |
LYHZXMVNRVAAJA-QAETUUGQSA-N
|
| InChi Code |
InChI=1S/C22H40N6O7/c23-11-3-1-6-15(26-19(31)14-8-5-13-25-14)20(32)27-16(9-10-18(29)30)21(33)28-17(22(34)35)7-2-4-12-24/h14-17,25H,1-13,23-24H2,(H,26,31)(H,27,32)(H,28,33)(H,29,30)(H,34,35)/t14-,15-,16-,17-/m0/s1
|
| Chemical Name |
(2S)-6-amino-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-pyrrolidine-2-carbonyl]amino]hexanoyl]amino]-4-carboxybutanoyl]amino]hexanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9976 mL | 9.9882 mL | 19.9764 mL | |
| 5 mM | 0.3995 mL | 1.9976 mL | 3.9953 mL | |
| 10 mM | 0.1998 mL | 0.9988 mL | 1.9976 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
